Larimar Therapeutics, Inc.
LRMR•NASDAQ•Healthcare•Biotechnology

About Larimar Therapeutics

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOCarole Ben-Maimon
Employees65
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitelarimartx.com
Phone844 511 9056
Address
Three Bala Plaza East, Suite 506 Bala Cynwyd, Pennsylvania 19004 United States

Corporate Identifiers

CIK0001374690
CUSIP517125100
ISINUS5171251003
EIN20-3857670
SIC2834

Leadership Team & Key Executives

Dr. Carole S. Ben-Maimon M.D.
Chief Executive Officer, President and Director
Michael Celano CPA
Secretary and Chief Financial Officer
Dr. Gopi Shankar M.B.A., Ph.D.
Chief Development Officer
John Berman
Vice President of Finance and Administration
Jennifer Spokes Johansson
Vice President of Legal and Compliance
Dr. Russell G. Clayton Sr., D.O.
Chief Medical Officer
Francis Michael Conway CPA
Vice President and Controller